Why the study?
Randomized controlled trials of TEER for SMR and TR have methodological issues challenging interpretation, prompting a need to overview TEER registries, clinical characteristics, outcomes, and data limitations.
Current TEER registries for heart failure patients with SMR or TR suffer from significant methodological limitations, highlighting the need for a novel conceptual framework for future prospective registries.
Answers are grounded in this paper and cite their sources.
Registry data on TEER for SMR and TR should be interpreted with caution; leaves open reliable outcome assessment and extends need for standardized prospective registries.
AIMS: Secondary mitral regurgitation (SMR) and tricuspid regurgitation (TR) are the most common valvular heart diseases in patients with heart failure (HF). Transcatheter edge-to-edge repair (TEER) devices designed for treating MR and TR have been successfully tested in randomized controlled trials, but methodological issues have often challenged their interpretation. This manuscript aimed to provide an overview of TEER registries on SMR and TR in HF, highlighting their key features, describing clinical characteristics and outcomes of patients receiving these devices, and exploring the available data limitations. METHODS AND RESULTS: PubMed, Web of Science, and EMBASE were searched for registries reporting on TEER in SMR or TR. Registries were excluded if single-centre and with <100 patients. Twenty-six registries (46% prospective, 12% ongoing), including a total cohort of 18 925 patients, were retrieved for TEER in SMR, and six registries (50% retrospective, 33% ongoing) reported on the use of TEER for TR in a total cohort of 1412 patients. Limited geographical representativity outside North America and Europe, high number of missing values, and inconsistency in data reporting were the main existing evidence limitations. CONCLUSION: Registries on TEER represent a key data source in a setting where it is difficult to conduct randomized controlled trials. However, limitations in design, patient characterization, and outcomes reporting restrain their use. A novel conceptual framework for future prospective TEER registries, as proposed in this document, might inform current practice, address relevant clinical questions and future trial design.
No takes yet. Share an insight, caveat, or question.
Savarese et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: